CUPERTINO, Calif., Oct. 5 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the BIO Emerging
Company Investor Forum. The conference is being held at The Palace Hotel in
San Francisco, CA. Dr. Felix Theeuwes, Chairman and Chief Scientific Officer,
will be presenting at the conference on Monday, October 14, 2004 at 11:30 a.m.
Pacific Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
A live audio webcast of the presentation will be available by accessing
DURECT’s homepage at http://www.www.durect.com and clicking “Investor Relations.”
About DURECT Corporation
DURECT Corporation is a pharmaceutical company focused on the development
of pharmaceutical systems based on its proprietary drug delivery platform
technologies that treat chronic debilitating diseases and enable biotechnology
products. These platform technologies include the SABER(TM) Delivery System
(a patented and versatile depot injectable useful for protein and small
molecule delivery), the ORADUR(TM) sustained release oral gel-cap technology
(an oral sustained release technology with several potential abuse deterrent
properties), the DURIN(TM) Biodegradable Implant (drug-loaded implant system)
and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable
system). DURECT also partners with pharmaceutical companies to develop and
commercialize proprietary and enhanced pharmaceutical products based on its
technologies. DURECT has four disclosed on-going development programs of which
three are in collaboration with pharmaceutical partners. Additional
information about DURECT is available at www.www.durect.com.
NOTE: SABER(TM), ORADUR(TM), DURIN(TM) and MICRODUR(TM) are trademarks of
DURECT Corporation.
The statements in this press release regarding DURECT’s products in
development, product development plans, anticipated clinical trials and
potential markets are forward-looking statements involving risks and
uncertainties that can cause actual results to differ materially from those in
such forward-looking statements. Potential risks and uncertainties include,
but are not limited to, DURECT’s abilities to complete the design,
development, and manufacturing process development of these products,
manufacture and commercialize these products, obtain product and manufacturing
approvals from regulatory agencies as well as marketplace acceptance of these
products. Further information regarding these and other risks is included in
DURECT’s Annual Report on Form 10-K for the fiscal year ended December 31,
2003 filed with the SEC on March 11, 2004, DURECT’s Quarterly Report on Form
10-Q and other periodic reports filed with the SEC under the heading “Factors
that may affect future results.”
SOURCE DURECT Corporation
/CONTACT: Schond L. Greenway, Executive Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840/
/Web site: http://www.www.durect.com /